PMID- 32867644 OWN - NLM STAT- MEDLINE DCOM- 20210325 LR - 20210325 IS - 1875-6417 (Electronic) IS - 1573-3998 (Linking) VI - 17 IP - 3 DP - 2021 TI - Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction. PG - 280-292 LID - 10.2174/1573399816999200821164129 [doi] AB - BACKGROUND: The major cardiovascular outcome trials on glucagon-like peptide one-receptor agonists have examined its effect on hospitalization of subjects with heart failure; however, very limited trials have been conducted on subjects with reduced left ventricular ejection fraction (r- LVEF) as a primary outcome. OBJECTIVE: We have conducted a systematic review of two major (FIGHT and LIVE) placebo-controlled trials of liraglutide and its clinical effect on the ejection fraction of subjects with heart failure. METHODS: Medline data was retrieved for trials involving liraglutide from 2012 to 2020. The inclusion criteria for trials were: subjects with or without type 2 diabetes mellitus (T2DM), subjects with heart failure with rLVEF, major trials (phase II or III) on liraglutide, trials included liraglutide with defined efficacy primary outcome of patients with heart failure with rLVEF. The search was limited to the English language, whereby two trials [FIGHT and LIVE] had been included and two trials were excluded due to different primary outcomes. Participants (541) had been randomized for either liraglutide or placebo for 24 weeks. RESULTS: In the FIGHT trial the primary intention-to-treat, sensitivity, and diabetes subgroup analyses have shown no significant between-group difference in the global rank scores (mean rank of 146 in the liraglutide group versus 156 in the placebo group; Wilcoxon rank-sum P=.31), number of deaths, re-hospitalizations for heart failure, or the composite of death or change in NT-pro BNP level (P= .94). In the LIVE trial, the change in the left ventricular ejection fraction (LVEF) from baseline to week 24 was not significantly different between treatment groups. The overall discontinuation rate of liraglutide was high in the FIGHT trial (29%, 86) as compared to that in the LIVE trial (11.6%, 28). CONCLUSION: FIGHT and LIVE trials have demonstrated that liraglutide use in subjects with heart failure and rLVEF was implicated with an increased adverse risk of heart failure-related outcomes. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Hamad, Farah AU - Hamad F AD - Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates. FAU - Elnour, Asim Ahmed AU - Elnour AA AD - Al Ain University, Abu Dhabi, United Arab Emirates. FAU - Elamin, Abdelgadir AU - Elamin A AD - Medical Laboratory Sciences, College of Health Sciences, Gulf Medical University, Ajman, United Arab Emirates. FAU - Mohamed, Sasha AU - Mohamed S AD - Clinical Pharmacy, College of Pharmacy, Riyadh Elm University Riyadh, Saudi Arabia. FAU - Yousif, Isra AU - Yousif I AD - Clinical Pharmacist, Omdurman Islamic University, Omdurman, Sudan. FAU - Don, Judit AU - Don J AD - College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates. FAU - Abdi, Semira AU - Abdi S AD - Pharmacy Practice, College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates. FAU - Al Amoodi, Abdulla AU - Al Amoodi A AD - Ambulatory Healthcare Services, Academic Affairs, Abu Dhabi Health Services (SEHA), United Arab Emirates. FAU - Fathelrahman, Ahmed Ibrahim AU - Fathelrahman AI AD - Department of Clinical Pharmacy, College of Pharmacy, Taif University, Saudi Arabia. FAU - Gnana, Kishore AU - Gnana K AD - Al Ain University, Abu Dhabi, United Arab Emirates. FAU - Alanzi, Fahad AU - Alanzi F AD - Physical Therapy Department, College of Applied Medical Sciences, Jouf-University, Saudi Arabia. FAU - Abubakar, Abubakar B AU - Abubakar AB AD - Department of Medical Imaging and Radiation Sciences, Monash University, Malaysia. FAU - Magboul, Salma Mohammed AU - Magboul SM AD - College of Pharmacy, Khartoum University, Khartoum, Sudan. FAU - Ahmed, Sahar Asim AU - Ahmed SA AD - MySmile Dental Clinic, Dubai, United Arab Emirates. FAU - Sadeq, Adel AU - Sadeq A AD - Program of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, United Arab Emirates. LA - eng PT - Journal Article PT - Systematic Review PL - United Arab Emirates TA - Curr Diabetes Rev JT - Current diabetes reviews JID - 101253260 RN - 0 (Glucagon-Like Peptide Receptors) RN - 0 (Glucagon-Like Peptide-1 Receptor) RN - 839I73S42A (Liraglutide) SB - IM MH - *Diabetes Mellitus, Type 2/complications/drug therapy MH - Double-Blind Method MH - Glucagon-Like Peptide Receptors MH - Glucagon-Like Peptide-1 Receptor MH - *Heart Failure/drug therapy MH - Humans MH - Liraglutide/therapeutic use MH - Stroke Volume MH - Treatment Outcome MH - Ventricular Function, Left OTO - NOTNLM OT - Glucagon-Like Peptide One Receptor Agonist (GLP-1 RA) OT - Heart Failure (HF) OT - Left Ventricular Ejection Fraction (LVEF) OT - Placebo-Controlled Randomized Clinical Trial (PC-RCT) OT - Randomized Clinical Trial (RCT) OT - liraglutide OT - reduced Left Ventricular Ejection Fraction (rLVEF) EDAT- 2020/09/02 06:00 MHDA- 2021/03/26 06:00 CRDT- 2020/09/02 06:00 PHST- 2020/06/26 00:00 [received] PHST- 2020/07/06 00:00 [revised] PHST- 2020/08/07 00:00 [accepted] PHST- 2020/09/02 06:00 [pubmed] PHST- 2021/03/26 06:00 [medline] PHST- 2020/09/02 06:00 [entrez] AID - CDR-EPUB-109426 [pii] AID - 10.2174/1573399816999200821164129 [doi] PST - ppublish SO - Curr Diabetes Rev. 2021;17(3):280-292. doi: 10.2174/1573399816999200821164129.